hVIVO (LON:HVO) Shares Up 13% - Still a Buy?

Key Points

• hVIVO plc shares surged by 13%, reaching GBX 8 ($0.11) during mid-day trading, a notable increase in volume of 223% compared to its average.
• Wall Street analysts maintain a positive outlook with an average rating of "Buy" and a target price of GBX 23, although some firms have adjusted their price targets downwards.
• The company specializes in pharmaceutical services and clinical trials, focusing on testing vaccines and antivirals through human challenge studies for various diseases.

hVIVO plc (LON:HVO - Get Free Report) shot up 13% during mid-day trading on Monday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). 9,588,585 shares changed hands during trading, an increase of 223% from the average session volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Wall Street Analyst Weigh In

A number of research firms recently issued reports on HVO. Peel Hunt restated an "add" rating and set a GBX 21 target price on shares of hVIVO in a research report on Tuesday, July 29th. Shore Capital cut their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of GBX 23.

hVIVO Stock Up 13.0%

The firm has a market cap of £53.60 million, a PE ratio of 1,012.99 and a beta of 0.97. The business's 50 day moving average price is GBX 9.27 and its 200 day moving average price is GBX 12. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.